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Downstream effects of plectin mutations in
epidermolysis bullosa simplex with
muscular dystrophy
Lilli Winter1†, Matthias Türk2†, Patrick N. Harter3, Michel Mittelbronn3, Cornelia Kornblum4,5, Fiona Norwood6,
Heinz Jungbluth7,8,9, Christian T. Thiel10, Ursula Schlötzer-Schrehardt11 and Rolf Schröder1*
Abstract
Mutations of the human plectin gene (PLEC) on chromosome 8q24 cause autosomal recessive epidermolysis bullosa
simplex with muscular dystrophy (EBS-MD). In the present study we analyzed the downstream effects of PLEC
mutations on plectin protein expression and localization, the structure of the extrasarcomeric desmin cytoskeleton,
protein aggregate formation and mitochondrial distribution in skeletal muscle tissue from three EBS-MD patients.
PLEC gene analysis in a not previously reported 35-year-old EBS-MD patient with additional disease features of
cardiomyopathy and malignant arrhythmias revealed novel compound heterozygous (p.(Phe755del) and
p.(Lys1040Argfs*139)) mutations resulting in complete abolition of plectin protein expression. In contrast, the other two
patients with different homozygous PLEC mutations showed preserved plectin protein expression with one only
expressing rodless plectin variants, and the other markedly reduced protein levels. Analysis of skeletal muscle tissue
from all three patients revealed severe disruption of the extrasarcomeric intermediate filament cytoskeleton, protein
aggregates positive for desmin, syncoilin, and synemin, degenerative myofibrillar changes, and mitochondrial
abnormalities comprising respiratory chain dysfunction and an altered organelle distribution and amount.
Our study demonstrates that EBS-MD causing PLEC mutations universally result in a desmin protein aggregate
myopathy phenotype despite marked differences in individual plectin protein expression patterns. Since plectin is the
key cytolinker protein that regulates the structural and functional organization of desmin filaments, the defective
anchorage and spacing of assembled desmin filaments is the key pathogenetic event that triggers the formation of
desmin protein aggregates as well as secondary mitochondrial pathology.
Keywords: Plectin, Epidermolysis bullosa simplex with muscular dystrophy, Skeletal muscle, Intermediate filaments,
Mitochondria, Desmin, Protein aggregates
Introduction
Plectin, a multi-domain protein of exceptionally large size
(>500 kDa), is abundantly expressed in a wide range of
mammalian cells and tissues, most prominently in muscle,
brain and stratified squamous epithelia [20]. It acts as a
multi-functional linker protein and signalling scaffold that
centrally orchestrates the structural and functional
organization of filamentous cytoskeletal networks, thereby
contributing to fundamental biomechanical properties of
mechanical stress-bearing tissue [21]. The essential
role of plectin in the latter is highlighted by the ob-
servation that mutations in the human plectin gene
(PLEC) on chromosome 8q24 cause a variety of rare
human disorders (referred to as “plectinopathies”), namely
autosomal recessive epidermolysis bullosa simplex with
muscular dystrophy (EBS-MD, MIM #226670), EBS-MD
with myasthenic features (EBS-MD-MyS), limb girdle
muscular dystrophy type 2Q (LGMD2Q, MIM #613723),
EBS with pyloric atresia (EBS-PA, MIM #612138), and the
autosomal dominant variant EBS-Ogna [23, 25]. While
the skin blistering in plectinopathies has been attributed
on the molecular level to a disruption of the normal kera-
tin intermediate filament (IF) anchorage to hemidesmosomes
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[21], the downstream effects of plectin mutations in
striated muscle are less clearly defined and to date have
only been addressed in very few detailed studies [2, 17].
Here we report the clinical, genetic, myopathological,
and biochemical findings in a not previously reported
German EBS-MD patient with additional features of car-
diomyopathy and malignant arrhythmias. Furthermore,
we analyse the downstream effects of his novel disease-
causing compound heterozygous PLEC mutations and
two other homozygous PLEC mutations on i) plectin
protein expression, ii) the structure of the extrasarco-
meric desmin cytoskeleton, iii) protein aggregate forma-
tion and iv) the subcellular distribution and biochemical
properties of mitochondria in skeletal muscle tissue.
Materials and methods
Patients
This study was approved by the local Ethics committees of
each participating institution. Written informed consent
was obtained from all participants. Patient 1 is a not previ-
ously reported, 35-year-old male patient of German origin
with EBS-MD. Patient 2 is a previously reported German
female with EBS-MD due to a homozygous 16-bp insertion
frameshift-mutation c.13459_13474dup (NM_000445.3) in
the 3′end of exon 32 of the PLEC gene, causing a prema-
ture termination codon (p.(Glu4492Glyfs*48)) [17] (see also
Fig. 1a). She had last been seen for clinical evaluation at the
age of 25 years but subsequently had tragically died in a do-
mestic fire accident. Patient 3 is a 24-year-old British female
with EBS-MD caused by a homozygous 19-bp deletion
frameshift-mutation c.5018_5036del (NM_000445.3) in
exon 31, which causes a premature termination codon
(p.(Leu1673Argfs*64)) [11] (see also Fig. 1a). See Table 1 for
more detailed clinical information of all three patients.
Genetic studies
DNA of patient 1 and his parents was fragmented
and enriched using the TruSight one enrichment kit
(Illumina, San Diego, USA). Sequencing was performed
on a MiSeq (Illumina, San Diego, USA) in paired-end
reads (2× 200 bp). After duplicate removal and quality
control the sequence reads were mapped with the BWA
aligner [9] to the reference genome (hg19). Variants were
called using 5 different calling programs (GATK, SNVer,
CASAVA, SOAPSNP and SOAPindel) and filtered based
on population frequency (<0.001 in 94 in house controls
and exomes of the ExAC consortium), position (exon
and splice site) and mutational effect (CADD score,
Polyphen2, SIFT, MutationTaster). Graphical presenta-
tion of the mapped sequences was viewed with the
Integrative Genomics Viewer (IGV) [14]. The result-
ing variants were Sanger sequenced and the segrega-
tion in the family confirmed.
Muscle biopsies and myopathological analyses
Patient 1 had a diagnostic muscle biopsy from his left
triceps brachii muscle in 2013. Skeletal muscle tissue
(left quadriceps) from patient 2 obtained as part of the
diagnostic process in 2001 was reevaluated. Patient 3
underwent a muscle biopsy from her left biceps humeri
in 2014. Skeletal muscle tissue was used for histochem-
ical studies by standard methods [4]. Immunofluores-
cence microscopy was performed on frozen muscle
sections (5 μm) using guinea pig antiserum (AS) to plectin
(Progen, GP-21; recognizing the C-terminal domain of
plectin, aa 4367–4684 in exon 32), mouse monoclonal
antibodies (mAbs) to plectin (KeraFAST, PN643; recog-
nizing the N-terminal actin binding domain, aa 171–595),
mAbs to desmin (Dako, clone D33), rabbit AS to
synemin 3 (D. Paulin, France, [26]), goat AS to syn-
coilin (Santa Cruz Biotechnology Inc., sc-162284), and
mAbs to complex IV (subunit I, Invitrogen, #459600)
in combination with donkey anti-guineapig IgG Alexa
Fluor 555, goat anti-mouse IgG Alexa Fluor 488, don-
key anti-mouse IgG Alexa Fluor 555, donkey anti-
rabbit IgG Alexa Fluor 488, and donkey anti-goat IgG
Alexa Fluor 488 (all from Life Technologies). Images
were acquired using a Zeiss LSM 780 confocal laser
scanning microscope.
Western blot analyses
Skeletal muscle tissue was homogenized in lysis buffer
(pH 6.8) containing 5 mM Tris, 10 % SDS, 0.2 M DTT,
1 mM EDTA, 100 mM NaF, 50 mM ß-glycerphosphate,
2 mM Na3VO4, 1 mM PMSF, and Complete mini prote-
ase inhibitor cocktail (Roche) using a TissueLyser II
(Qiagen; 30×/s, 2 min; three repetitions). The homogenate
was centrifuged for 10 min at 13,000 rpm and the super-
natant was stored at −20 °C. For gel electrophoresis, the
tissue homogenate was mixed with SDS-sample buffer,
denatured at 95 °C for 5 min, and loaded onto 4–15 %
Mini-PROTEAN® TGX™ Precast Gels (BioRad). Proteins
were transferred onto nitrocellulose membranes, and the
following primary antibodies were used for immunoblot
analyses: guinea pig AS to plectin (Progen, GP-21; recog-
nizing the C-terminal domain of plectin, aa 4367–4684 in
exon 32), rabbit AS to plectin (#9, G. Wiche, Austria; rec-
ognizing plectin exons 9–12, [1]), rabbit AS to desmin
(Abcam, ab8592), rabbit AS to synemin 3 (D. Paulin,
France, [26]), goat AS to syncoilin (Santa Cruz Biotechnol-
ogy Inc., sc-162284), mAbs to α-actinin (Sigma, #7811),
mAbs to GAPDH (Sigma, G8795), mAbs to complex
II (70 kDa Fp Subunit, Invitrogen, # 459200), mAbs
to complex V (α-subunit, Invitrogen, #439800). For
detection, HRP-conjugated secondary antibodies (all
from BioRad) in combination with Pierce SuperSignal
West Pico Chemiluminescent Substrate (Thermo Sci-
entific) were used.
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Results
Novel compound heterozygous PLEC mutations lead to
EBS-MD plus cardiomyopathy and life-threatening
arrhythmias
Patient 1 is a 35-year-old German male with a past med-
ical history of skin blistering (Fig. 1b) and nail dystrophy
(Fig. 1c) since birth. At the age of 27 he first experienced
recurrent episodes of dizziness and sudden loss of con-
sciousness. Cardiological evaluation at that time revealed
a dilated cardiomyopathy with markedly reduced left
ventricular ejection fraction (20–30 %), as well as epi-
sodes characterized by self-limiting ventricular fibrilla-
tion and torsades. Since the cardiac arrhythmias were
graded as life-threatening, a single-chamber cardioverter
defibrillator was implanted (see asterisk in Fig. 1d).
Slowly progressive muscle weakness and myalgia were
first noted soon after the manifestation of cardiac
problems. Neurological examination at the age of 32
revealed muscle weakness and wasting predominantly
affecting shoulder-girdle and lower leg muscles with
an associated marked steppage gait (Fig. 1d and e).
Needle electromyography revealed a myopathic pat-
tern in proximal and distal muscles of both the upper
and lower limbs. CK levels were markedly elevated
(up to 3782 IU/l). PLEC sequencing revealed two
novel heterozygous variants, a maternally inherited in-
frame deletion c.2264_2266delTCT/p.(Phe755del) in
exon 19 and a paternally inherited frameshift deletion
Fig. 1 Schematic representation of the localization of the PLEC mutations identified and clinical features of EBS-MD. a Schematic domain map of
plectin and positional mapping of the EBS-MD mutations studied in this work. The tripartite structure of the plectin molecule comprises a central,
α-helical rod domain (blue), which is flanked by N- and C-terminal globular domains. The N-terminal domain harbors an actin-binding domain
(ABD, yellow) and a plakin domain (green), whereas the C-terminal domain consists of six highly homologous plectin repeat domains (red), harboring
an intermediate filament-binding domain (IFBD) between repeat 5 and 6. Note that EBS-MD 1 is compound heterozygous, whereas EBS-MD2 and 3
are homozygous mutations. Binding sites of antibodies PN643 and #9, recognizing plectin’s N-terminal region, and GP-21 antibodies, recognizing
plectin’s C-terminal region, are indicated in blue. b Large erythematous skin blister (arrow) on the proximal forearm of patient 1. c Nail dystrophy of
the right index finger (arrow) and small skin blisters (arrowheads) of patient 1. d Muscle atrophy of the upper extremity in patient 1. Asterisk indicates
the scar from the implantation of the cardioverter defibrillator. e Distal muscle atrophy of the lower extremities with inability to stand on heels. Note
the multiple skin lesions of patient 1 (arrows)
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c.3119_3120delAA/p.(Lys1040Argfs*139) in exon 24
(see Additional file 1: Figure S1 and Table 1). Both are
classified as pathogenic according to the ACMG criteria
and are therefore considered disease causing variants.
Impact of PLEC mutations on skeletal muscle morphology
and plectin protein levels: no plectin, less plectin, or
expression of rodless plectin
Myopathological analyses of skeletal muscle specimens
from all three EBS-MD patients with genetically con-
firmed PLEC mutations revealed a marked myodegen-
erative pattern with increased endomysial connective
and fatty tissue, highly variable fiber size diameters (5 to
145 μm), predominance of type 1 fibers, fiber splitting as
well as de- and regenerating fibers (Fig. 2a). Quantifica-
tion of muscle fibers with internally located myonuclei
demonstrated an abnormal myonuclear positioning in
47 % of fibers in patient 1, in 55 % of fibers in patient 2
and in 10 % of fibers in patient 3. Muscle biopsy from
patient 2 additionally showed multiple muscle fibers
with rimmed vacuoles (data not shown). To investigate
the effects of the three different PLEC mutations on
plectin protein expression in skeletal muscle, we per-
formed indirect immunofluorescence microscopy and
immunoblot analyses using plectin-specific antibodies
(Fig. 2b-d). These analyses showed a marked variation of
plectin protein levels among the three EBS-MD cases.
Immunofluorescence analysis using antibodies directed
against the N-terminal or the C-terminal part of plectin
demonstrated the complete absence of specific immuno-
staining in patient 1, whereas the other two EBS-MD
muscle specimens displayed markedly reduced plectin
staining in comparison to normal controls (Fig. 2b).
Plectin immunoblot analysis of normal human skeletal
muscle detected two bands, one with a strong signal in-
tensity corresponding to a molecular mass of approxi-
mately 500 kDa and a second, very faint signal at
390 kDa. While the former represents the full length
plectin protein species, the latter corresponds to rodless
plectin variants [13]. Analysis of patient 1 showed a
complete absence of plectin, whereas patient 2 displayed
a marked reduction in the signal intensities of both
bands. In contrast, analysis of the muscle probe from pa-
tient 3 resulted in the sole detection of rodless plectin
variants (Fig. 2c and d, and Table 1). Thus, the PLEC
mutations in our three EBS-MD patients led to marked
individual differences in plectin protein expression in
skeletal muscle.
Aberrant plectin expression leads to destruction of the
desmin network and desmin protein aggregation
pathology
One major function of plectin in skeletal muscle is the
proper organization and anchorage of the three-
dimensional, extrasarcomeric IF network, which – in
addition to plectin - is mainly composed of the IF pro-
teins desmin, syncoilin, synemin [7, 16]. In contrast to
the regular IF staining pattern in normal controls, our
Table 1 Genetic, clinical and myopathological features of EBS-MD patients
Pat. PLEC-Mutations and their effects on plectin
protein expession
Clinical phenotype Myopathological findings
1, m ▪ compound heterozygous
▪ exon 19: c.2264_2266delTCT/p.(Phe755del)
(in-frame deletion)
▪ exon 24: c.3119_3120delAA/p.(Lys1040Argfs*139)
(premature termination codon)
➢ no detectable plectin protein expression
▪ EBS: since birth
▪ myopathy: generalized; predominantly
affecting shoulder-girdle and lower leg
muscles
▪ dilated cardiomyopathy; ventricular
arrhythmias
▪ LM: myopathic pattern; fibers with
rubbed-out lesions; desmin-protein
aggregates
▪ EM: degenerating myofibrills;
autophagic vacuoles (triceps
muscle; age at biopsy: 33 years)
2, f [17] ▪ homozygous
▪ exon 32: c.13459_13474dup/p.(Glu4492Glyfs*48)
(premature termination codon)
➢ reduced plectin protein expression
(full-length and rodless)
▪ EBS: since birth
▪ myopathy: generalized; predominantly
affecting proximal muscle groups; facial
weakness; marked bilateral ptosis; incomplete
external ophthalmoplegia,
▪ mild left ventricular cardiac hypertrophy
▪ bilateral cataracts
▪ brain atrophy with hydrocephalus ex vacuo
▪ LM: myopathic pattern; rimmed-
vacuoles; fibers with rubbed-out
lesions; desmin-protein aggregates
▪ EM: degenerating myofibrils;
cytoplasmic bodies; abnormally
shaped mitochondria with
paracristalline inclusions; desmin-
positive filaments and sub-
sarcolemmal protein aggregates
(quadriceps muscle; age at biopsy:
25 years)
3, f [11] ▪ homozygous
▪ exon 31: c.5018_5036del/p.(Leu1673Argfs*64)
(premature termination codon)
➢ expression of rodless plectin protein only
▪ EBS: since birth
▪ myopathy: mild neck flexion, shoulder
abduction, elbow flexion and hand muscle
weakness
▪ inspiratory stridor in the postnatal period due
to moderate supraglottic obstruction caused
by interarytenoid scarring
▪ LM: myopathic pattern; fibers with
rubbed-out lesions; COX-negative
fibers; desmin-protein aggregates
▪ EM: not performed
(biceps muscle; age at biopsy 24 years)
Plectin mutations are assigned to a common reference sequence, GenBank accession number NM_000445.3. Pat. indicates patient; m, male; f, female; yrs, years;
LM, light microscopy; EM, electron microscopy
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Fig. 2 Skeletal muscle pathology and plectin expression in EBS-MD muscle. a Skeletal muscle sections from a healthy control and patients 1–3
were stained by hematoxylin and eosin. Note the rounding of muscle fibers with marked variation in fiber size, internalization and clustering of
myonuclei, and increased amount of connective tissue in EBS-MD patient muscles. Scale bar: 50 μm. b Immunofluorescence microscopy of skeletal
muscle sections from a healthy control and patients 1–3 using antibodies PN643, regognizing the N-terminal actin binding domain (aa 171–595),
and GP-21, recognizing plectin’s C-terminus (aa 4367–4684 in exon 32). Nuclei were visualized using Dapi. Note the drastically reduced plectin
staining intensity in muscle tissue from patients 2 and 3, as well as the completely absent staining in patient 1. Scale bar: 50 μm. c and d Immunoblotting
of cell lysates prepared from patient 1 (c), patients 2 and 3 (d), and a healthy control. Antibodies used for detection are indicated. GAPDH was used as
loading control. Note that plectin antibody GP-21 detects plectin’s C-terminal region (aa 4367–4684 in exon 32), whereas plectin antiserum #9 recognizes
the N-terminal region (exons 9–12). While no plectin band could be detected in patient 1, markedly reduced but still recognizable plectin levels were
observed in patient 2. Patient 3 had no expression of full-length plectin, while rodless plectin was still found
Winter et al. Acta Neuropathologica Communications  (2016) 4:44 Page 5 of 10
immunofluorescence analyses on muscle tissue from
EBS-MD patients using corresponding antibodies demon-
strated a marked disruption of the endogenous desmin
network in conjunction with subsarcolemmal and sarco-
plasmic desmin-, syncoilin-, and synemin-positive protein
aggregates in nearly all muscle fibers (Fig. 3a and b). Sub-
sequent immunoblot analyses of all three EBS-MD probes
revealed significantly increased desmin protein levels
(180 % in patient 1; 156 % in patient 2 and 242 % in pa-
tient 3), whereas the levels of syncoilin and synemin were
unchanged (Fig. 3c and d). Thus, irrespective of the indi-
vidual PLEC mutations and their corresponding plectin
protein expression pattern, these patients universally ex-
hibited destruction of the desmin filament network and
desmin-positive protein aggregates, which are the hall-
marks of the EBS-MD muscle pathology.
From cytoskeletal to mitochondrial pathology in EBS-MD
muscle tissue
Structural and functional alterations of mitochondrial
networks have previously been described in skeletal
muscle specimens from EBS-MD patients [10, 17] as
well as muscle-restricted conditional plectin knockout
mice [7]. Succinate dehydrogenase (SDH) and cyto-
chrome oxidase (COX) stains of muscle specimens from
our EBS-MD patients clearly demonstrated an abnormal
pattern with less ordered, often coarse, and thread-like
appearing mitochondrial networks (Fig. 4a). Moreover,
in a subset of fibers, large sarcoplasmic areas with mark-
edly attenuated enzyme staining (“rubbed-out” lesions)
became apparent (Fig. 4a, arrows). In addition, several
COX-negative/SDH-positive fibers were identified in the
muscle biopsy from patient 3 (Fig. 4a, arrowheads).
However, no classical ragged-red fibers were seen in
Gomori-Trichrome stains (data not shown). In keeping
with the enzymatic COX stains, immunofluorescence
analysis using a complex IV antibody showed reduced
signal intensities in all EBS-MD samples (Fig. 4b). Fur-
thermore, immunoblotting with antibodies directed
against complex II and V of respiratory chain enzymes
revealed a dramatic decrease of the respective expression
levels in all EBS-MD samples (Fig. 4c). Expression levels
of complex II were reduced to 42 % (patient 1), 52 %
(patient 2), or 67 % (patient 3), and complex V to to
41 % (patient 1), 50 % (patient 2), or 44 % (patient 3)
compared to control levels (Fig. 4d). In addition to
changes in the subcellular distribution of mitochondria,
the decrease in the levels of complex II, IV and V suggest
a reduction in the total amount of mitochondria in EBS-
MD muscle tissue.
Discussion
Our genetic analysis in patient 1 identified two novel
compound heterozygous PLEC mutations. In addition to
the skin and skeletal muscle involvement characteristic
of the disease, this patient developed a dilated cardiomy-
opathy and life-threatening episodes of cardiac arrhyth-
mias necessitating the implantation of a single-chamber
cardioverter defibrillator. Plectin-related cardiac disease
comprising mild left ventricular hypertrophy [17], reduced
ejection fraction in combination with artrial fibrillation
[3], dilated cardiomyopathy [2], and left ventricular non-
compaction cardiomyopathy [19] have previously been de-
scribed in a subset of EBS-MD patients. However, this is
the first report indicating that even life-threatening car-
diac disease manifestations may occur before the onset of
skeletal muscle symptoms, suggesting that regular cardio-
logical assessments including electrophysiological and car-
diac imaging studies should be part of the diagnostic
work-up of all EBS-MD patients.
To characterize the downstream effects of PLEC muta-
tions, we analysed skeletal muscle tissue from the newly-
reported patient in comparison to muscle biopsies from
two other previously reported EBS-MD patients, in
whom the homozygous disease-causing mutations reside
in exon 31 and exon 32 of the PLEC gene, respectively.
Our immunoblot studies demonstrated a heterogenous
pattern of plectin expression with complete abolition of
plectin protein expression in patient 1, markedly re-
duced plectin levels in patient 2, and the sole presence
of rodless plectin variants in patient 3. Rodless plectin
isoforms, lacking the central rod domain due to alterna-
tive splicing of exon 31 [5], are expressed in normal hu-
man skeletal muscle and skin tissue, though in relatively
low amounts [8, 16]. A recent study in plectin knock-in
mice indicated that rodless plectin might functionally
compensate for the loss of full-length plectin in murine
skin and skeletal muscle tissue [6]. However, this notion is
clearly contradicted by our findings in patient 3, who -
despite expressing rather high levels of rodless plectin in
muscle – developed a severe form of muscular dystrophy.
Irrespective of the individual PLEC mutations and
their varying consequences on plectin protein expres-
sion, our analyses revealed a rather uniform picture of
EBS-MD muscle pathology, characterized by degenerative
myofibrillar changes, subsarcolemmal and sarcoplasmic
desmin-positive protein aggregates, and mitochondrial ab-
normalities. Since these myopathological alterations are
also the morphological hallmark of myofibrillar myop-
athies [15, 18], EBS-MD can thus be classified as a subtype
of these protein aggregate myopathies.
Studies in primary human differentiating skeletal muscle
cells and various transgenic plectin mouse models indicate
that plectin exerts a pivotal role in the structural and func-
tional organization of the three-dimensional desmin IF
network, with an essential role in mechanosensing and in
protecting skeletal muscle cells against mechanical stress
[7, 16, 24]. Our study demonstrates universal disruption
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of the endogenous desmin-, synemin-, and syncoilin-IF
networks in nearly all EBS-MD skeletal muscle fibers.
Hence, the faulty subcellular spacing and anchorage of
preformed desmin filaments is the primary pathogenic key
event in EBS-MD striated muscle tissue. In keeping with
this notion, the only reported histopathological study of
cardiac muscle from an EBS-MD patient with dilated car-
diomyopathy revealed a disruption of the regular desmin
Fig. 3 Disruption and aggregation of IF networks in EBS-MD muscle. a Confocal imaging of desmin-stained skeletal muscle specimens from a
healthy control and EBS-MD patients. Panels i-iv are magnifications of the boxed areas in panel a. Note the formation of desmin-positive protein
aggregates in all EBS-MD samples. Scale bars: 50 μm (a), 25 μm (panels i-iv). b Skeletal muscle sections were co-stained for desmin and synemin
or syncoilin. Note that all three types of IFs lose their proper orientation in EBS-MD muscles and co-accumulate in desmin-positive protein aggregates.
Scale bar: 50 μm. c Immunoblotting of cell lysates prepared from EBS-MP patients and three healthy controls. Antibodies used for detection are
indicated. GAPDH and α-actinin were used as loading controls. d Signal intensities of desmin, syncoilin and synemin protein bands as
shown in (c) were densitometrically measured and normalized to the total protein content (assessed by GAPDH staining). Healthy controls
(dashed line) are set at 100 %. Mean values ± SEM, 3 replicates
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and plectin staining pattern at the level of Z-discs and in-
tercalated discs as well as the presence of desmin-positive
protein aggregates [2]. Furthermore, our previously re-
ported desmin immogold EM analysis of patient 2 demon-
strated the presence of subsarcolemmal and sarcoplasmic
protein aggregates, which are composed of preformed but
highly disordered desmin filaments [17]. Our new immu-
noblot studies further highlighted increased desmin pro-
tein levels in all EBS-MD samples indicating alterations in
the overall desmin protein homeostasis. Thus, increased
desmin protein levels in conjunction with the defective
anchorage and spacing of preformed desmin filaments
are the basis for the formation of subsarcolemmal
and sarcoplasmic protein aggregates, which are com-
posed of desmin, synemin-, and syncoilin IFs.
Previous studies in plectin and desmin knock-out mice
convincingly demonstrated that the formation of en-
dogenous plectin-desmin IF networks is pivotal for the
normal organization, content, function and regulation of
mitochondrial networks [7, 12, 22]. Hence, the observed
changes in the subcellular distribution and amount of
mitochondria as well as respiratory chain dysfunction in
Fig. 4 Mitochondrial alterations in EBS-MD muscle. a Skeletal muscle specimens from a healthy control and EBS-MD patients were histologically
double-stained for SDH and COX. Note the presence of “rubbed-out” areas (arrows), and the presence of COX-negative fibers in patient 3 (arrow-
heads). Scale bar: 50 μm. b Confocal imaging of mitochondrial respiratory complex IV-stained skeletal muscle specimens from a healthy control
and EBS-MD patients. Panels i-iv are magnifications of the boxed areas in panel b. Note the reduced staining intensity in all EBS-MD samples.
Scale bars: 50 μm (b), 25 μm (panels i-iv). c Immunoblotting of cell lysates prepared from EBS-MD patients and three healthy controls using anti-
bodies for mitochondrial respiratory complex II or V. α-Actinin was used as loading control. d Signal intensities of respiratory complex II or V pro-
tein bands as shown in (c) were densitometrically measured and normalized to the total protein content (assessed by α-actinin staining). Healthy
controls (dashed line) are set to 100 %. Mean values ± SEM, 3 replicates
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EBS-MD muscle are likely to be a direct consequence of
the primary and omnipresent disruption of the plectin-
desmin IF networks, rather than being an nonspecific
secondary effect of muscle degeneration. Thus, our study
strongly implies that the mitochondrial pathology is a
fundamental pathogenic mechanism that contributes to
the progressive and severe muscle damage in EBS-MD.
Conclusion
Our study demonstrates that EBS-MD causing PLEC
mutations, though leading to marked differences in the
individual plectin protein expression pattern, all result in
a desmin protein aggregate myopathy phenotype. Since
plectin is the key cytolinker protein that regulates the
structural and functional organization of the desmin fila-
ments, the defective anchorage and spacing of assembled
desmin filaments is the key pathogenetic event that trig-
gers the formation of desmin protein aggregates as well
as the secondary mitochondrial pathology.
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